logo
logo

Invetx Announces Completion of $25.5 Million Series A Financing and Key Appointments to Executive Team

Sep 30, 2020almost 5 years ago

Amount Raised

$25 Million

Round Type

series a

Boston

Description

Invetx, a pioneer in protein-based therapeutics for animal health, announced today that it has raised an additional $10.25 million in its Series A financing, bringing the total amount to $25.5 million. New investors include Casdin Capital and funds managed by Tekla Capital Management, LLC, joining existing lead investor Anterra Capital, as well as strategic investors AbCellera Biologics and WuXi Biologics. In addition, Invetx announced the appointments of Bill Brondyk, PhD, as chief scientific officer and Colin Giles, PhD, as chief development officer to its executive team.

Company Information

Company

Invetx

Location

Boston, Massachusetts, United States

About

Our team of R&D leaders from human biotech and animal health is building the premier biotechnology platform for protein-based therapeutics in animal health.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People